Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.

@article{Brisson2016HealthAE,
  title={Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.},
  author={Marc Brisson and J. F. Laprise and Harrell W Chesson and M{\'e}lanie Drolet and Tal{\'i}a Malag{\'o}n and Marie-Claude Boily and Lauri Ellen Markowitz},
  journal={Journal of the National Cancer Institute},
  year={2016},
  volume={108 1}
}
BACKGROUND Randomized clinical trials have shown the 9-valent human papillomavirus (HPV) vaccine to be highly effective against types 31/33/45/52/58 compared with the 4-valent. Evidence on the added health and economic benefit of the 9-valent is required for policy decisions. We compare population-level effectiveness and cost-effectiveness of 9- and 4-valent HPV vaccination in the United States. METHODS We used a multitype individual-based transmission-dynamic model of HPV infection and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Bureau of Labor Statistics , Labor USDo . Consumer Price Index . Item Medical Care . Series CUUR 0000 SAM

  • N VandeVelde, MC Boily, M Drolet
  • MMWR Morb Mortal Wkly Rep .
  • 2014

Similar Papers

Loading similar papers…